-
The needle is beginning to move. Four key healthcare associated infections (HAIs) are declining nationally as the result of unprecedented interest and action that includes everything from sweeping state and federal collaboratives to the outrage of individual patients.
-
Doing the right thing doesn't guarantee that everyone is going to be pleased, says Frederick S. Southwick, MD, professor of medicine in the Division of Infectious Diseases and quality projects manager for the senior vice president for health affairs at the University of Florida Shands Health in Gainesville.
-
Emerging multidrug resistant gram negative bacteria continue to spread across the health care continuum, becoming entrenched in non-acute and long term care settings and threatening vulnerable hospital patients with untreatable infections.
-
Key program elements of a patient isolation program at the University of Chicago Medical Center include the following:
-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
With the increasing reliance on computer tools and electronic records, infection preventionists may reasonably assume patients flagged for isolation on admission end up under the appropriate precautions.
-
Hollywood movies have always created their own reality. Meanwhile, the rest of us slog through the conventional reality of our daily lives.
-
This study was conducted at the largest children's hospital in Taiwan. All pneumococcal isolates recovered from sterile sites from children hospitalized at this institution were maintained frozen at -20° C since 2000.
-
A total of 783 children 6-24 months of age were followed for an entire respiratory season by four experienced otoscopists using pneumatic otoscopy of one ear, randomly selected for each child.
-
Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxifloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy clinical trial design.